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Case presentation
A 14-year-old girl was admitted to Michael Reese Hospital for
evaluation and management of fluid and electrolyte imbalance. Four
years previously, she had been admitted to another hospital because of
headaches, lethargy, tunnel vision, and disorientation. She had under-
gone a craniotonly for removal of a dysgerminoma in the vicinity of the
optic chiasm. She also had received a course of postoperative irradia-
tion (2000 rads) directed at the suprasellar area. Polyuria developed and
was treated intermittently with vasopressin. Her neurologic status was
judged normal shortly following surgery, but neurologic deficits became
manifest later during the hospitalization. These deficits, which included
quadriparesis, intention tremors, difficulty with speech, and diminished
intellectual function, were ascribed to recurrent episodes of dehydra-
tion. The serum sodium concentration fluctuated widely, reaching a low
of 120 mEq/liter and a high of 179 mEq/liter, The patient denied thirst,
and polydipsia did not occur even during episodes of severe hypertonic
dehydration. Medications at discharge included vasopressin, levothy-
roxine, and cortisone. In addition, the patient's family was instructed to
encourage water and salt intake. One year later, vasopressin adminis-
tration was discontinued, and treatment with DDAVP by nasal insuffla-
tion was instituted.
Over the ensuing 2 years, the patient exhibited wide swings in plasma
Presentation of the Forum is made possible by grants from Smith Kline
& French Laboratories, CIBA Pharmaceutical Company, and GEIGY
Pharmaceuticals.
© 1984 by the International Society of Nephrology
sodium level, ranging from 112 to 168 mEq/liter. Three episodes
required hospitalization, and one was associated with seizures. One
month before admission to Michael Reese Hospital, she fell and struck
her head but did not loose consciousness. She began to complain of
headache and became more lethargic. One week later, she experienced
a seizure and was admitted to another hospital. The serum sodium
concentration was 128 mEq/liter. A CT scan of the head was unremark-
able. Phenytoin therapy was begun at a dose of 100 mg twice daily, and
she was discharged after 3 days. A second seizure occurred 36 hours
after discharge and she was readmitted to the hospital. The serum
sodium concentration was 112 mEq/liter. Saline solutions were adminis-
tered intravenously, and the phenytoin dose was increased to 200 mg
twice daily. Several days following discharge, her speech became more
slurred. She complained of constipation and shortly thereafter devel-
oped a morbilliform rash. On readmission to the hospital, the plasma
phenytoin level was found to be in the toxic range and the serum sodium
concentration was 165 mEq/liter. All medications were withheld, and
she was transferred to Michael Reese Hospital.
Physical examination revealed a lethargic young girl. The blood
pressure was 118/70 mm Hg; pulse, 90 per minute; respirations, 18 per
minute; and temperature, 35.4°C. The skin was erythematous with
evidence of a fading rash. All extremities were somewhat swollen. The
patient was disoriented and the previously described neurologic deficits
were present.
Laboratory examination revealed: hematocrit, 35%: hemoglobin,
11.6 g/dl; white blood cell count, 4000/mm7 with a normal differential;
random serum glucose, 144 mg/dl; serum sodium, 144 mEq/liter;
potassium, 4.2 mEq/liter; chloride, 109 mEq/liter; total CO2. 24 mM!
liter; plasma osmolality, 289 mOsm!kg; BUN, 19 mg!dl; and serum
creatinine, 0.9 mg!dl. The urine specific gravity was 1.025 and the urine
osmolality 758 mOsm/kg.
Administration of levothyroxine, 0.1 mg/day, and cortisone, 10 mg
twice daily, was reinstituted, but DDAVP was withheld. On the
following day, the urine specific gravity was 1.003 and the urine
osmolality was 197 mOsm!kg. On the third hospital day, plasma
osmolality was 317 mOsm!kg, urine osmolality was 89 mOsm!kg, and
the plasma vasopressin was less than 0.5 pg/mI. The patient was alert
but denied thirst and dia not drink unless specifically told to do so. She
was given DDAVP, 0.025 cc intranasally every 12 hours, and was
discharged with the recommendation that her daily fluid intake be
adjusted in accordance with fluctuations in daily weight.
Discussion
DR. GARY L. ROBERTSON (Director of the Clinical Research
Center and Professor of Medicine, University of Chicago,
Chicago, Illinois): The recurrent episodes of hyponatremia and
hypernatremia that affected this patient are a classic example of
the severe disturbances in water balance that accompany
complete loss of the osmoregulatory system. To fully under-
stand the cause and treatment of these disturbances, one needs
to understand how this homeostatic system operates in healthy
people. In reviewing the principal physiologic elements in the
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regulation of water balance in humans, I will emphasize the
thirst mechanism, because of its vital importance for osmoregu-
lation and because it is often neglected in discussions of water
balance. I also will touch on the regulation of antidiuretic
function, because it too plays an important role in controlling
water balance, and it is involved at least secondarily in the
abnormalities observed in this patient.
Physiology
In healthy adults, plasma osmolality and its principal determi-
nant, plasma sodium, usually are maintained within a relatively
narrow range, from about 275 to 295 mOsm/kg and 135 to 145
mEq/liter, respectively. This constancy is achieved largely by
rapid increases or decreases in body water that counteract
changes in the plasma concentration of sodium and certain
other solutes. These adjustments in body water are effected
when we alter the rate of water intake or excretion (or both);
these changes are mediated by changes in thirst or by changes
in the secretion of the antidiuretic hormone arginine vasopres-
sin [1].
Thirst is one of the more powerful of the behavioral drives.
When maximally stimulated in humans, the craving for water
cannot be ignored and can become sufficiently intense to
dominate all other thoughts and sensations. The compelling
nature of the thirst mechanism is appropriate for the vital role it
plays in human homeostasis. In healthy, sedentary adults in
temperate climates, the amount of water lost daily through the
skin, lungs, and kidneys generally approximates 2 liters, an
amount approximately equal to that acquired from an ordinary
diet and the metabolism of fat. With increases in activity or
environmental temperature, however, the amount of water lost
via respiration, perspiration, or both increases dramatically [2].
At the extremes of exertion or temperature, these evaporation
losses can reach 12 to 20 liters, or about one-third or one-half of
total body water, each day. Hence, to protect humans from the
morbid and sometimes fatal effects of hypertonic dehydration, a
mechanism is needed to ensure that water intake will always
offset water losses. This indispensable safeguard is provided by
the thirst mechanism.
Any meaningful exploration of the thirst mechanism must
proceed from a proper definition of the term. The issue has been
the subject of much debate, with major disagreement focusing
on whether it is a local (for example, pharyngeal) or general
sensation [3]. In this review, we will define thirst as a general-
ized, deep-seated feeling of a desire for water. As used here,
thirst is not synonymous with drinking, because the latter can
be affected positively or negatively by a variety of other factors.
Strictly speaking, moreover, this terminology is appropriate
only for human studies, as animals cannot report the sensation
of thirst or otherwise indicate the motive for water intake.
Study of the thirst mechanism has long been hampered by the
lack of objective methods of quantitation. Unlike some sensory
modalities such as vision or hearing, the activity of which can
be monitored via changes in electrical activity or blood flow in
certain parts of the brain, estimates of thirst rely solely on the
patient's ability to perceive and report the sensation. Some-
times one can check such information by observing the amount
of water drunk spontaneously. But often this approach is not
possible because ingestion of water would compromise the care
of the patient or counteract the particular stimulus being
studied. Clinical dipsologists therefore still must rely heavily on
subjective estimates of the intensity of thirst.
A geometric rating scale like that devised by Thompson and
Campbell [41 can be used to quantitate acute changes in thirst at
least in controlled, experimental settings. This approach was
used initially to measure the dipsogenic effects of 2-deoxy-D-
glucose [5], but it works equally well for assessing the effects of
osmotic stimuli (Fig. 1). Immediately before and at intervals
after infusion of a hypertonic solution, the subject places marks
to the right or left of successive horizontal lines according to
whether the sensation of thirst is more or less intense than
during the previous rating period. The magnitude of the change
is indicated by the horizontal distance between the marks. By
measuring the distance of each mark from the central vertical
line and relating this value to concurrent plasma osmolality, one
can construct a stimulus-response curve for the thirst mecha-
nism, which in its general form is similar to that for vasopressin
secretion (Fig. 2). Susceptible though it may be to distortion by
a variety of personal, cultural, and other unknown influences,
this method provides a semiquantitative, but best-available,
description of the function of the thirst mechanism. The esti-
mate of thirst intensity at the end of a hypertonic saline infusion
correlates positively with spontaneous fluid intake immediately
afterwards (Zerbe RL, Robertson GL, unpublished observa-
tions). A similar correlation is observed after administration of
2-deoxy-D-glucose, a nonosmotic dipsogen [4, 5]. Moreover,
infusion of isotonic saline or solutes such as glucose causes no
consistent change either in the thirst rating scale or water
intake. Finally, as one might predict on an a priori basis,
patients with adipsic hypernatremia show an absent thirst
response to hypertonic saline; this finding correlates well with
other laboratory evidence of osmoreceptor ablation.
In healthy adults, thirst is regulated largely, if not exclusively,
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Fig. 1. Thirst rating in a healthy adult at various times during the
infusion of hypertonic glucose () or hypertonic saline (o). Marks to the
right and left of the center line indicate, respectively, the degree of
increase or decrease in thirst at each time interval.
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Fig. 2. The relationship of plasma AVP (o) and thirst (x) to plasma
osmolality in a healthy volunteer during infusion of 5% saline. The
plasma AVP level was determined by radioimmunoassay. Thirst inten-
sity was estimated by means of a geometric rating scale (Fig. 1). The
regression functions were calculated by least-squares analysis of all
data pairs above the x-intercept.
by the effective osmotic pressure of plasma. This control ap-
pears to be mediated by a collection of osmosensitive neu-
rons located in the anterior hypothalamus near, but separate
from, the cell bodies of the neurohypophysis. These osmore-
ceptors can detect extremely small changes in the plasma
concentration of sodium and certain other solutes, and convert
this information into neural impulses that result in thirst.
Virtually nothing is known at present about either the mecha-
nism of this response or the location or cortical representation
of the afferent pathways that mediate this effect.
The osmoreceptors that control thirst have many properties
in common with those that regulate the secretion of arginine
vasopressin (AVP). Anatomically, the thirst osmoreceptors
appear to be located in similar if not identical areas in the
hypothalamus; lesions that interfere with the osmoregulation of
thirst almost invariably are associated with a comparable defect
in the osmoregulation of AVP. The two functions might even be
subserved by the same osmoreceptor neurons. However, this
possibility is not supported by animal studies that indicate
partial anatomic dissociation of thirst and ADH regulatory
areas [6, 7]. Furthermore, other data that I will discuss later
indicating that the "threshold" or "set" of the two systems is
different support the concept of separate anatomic sites. Never-
theless, both observations could be due to quantitative rather
than qualitative differences in response characteristics of the
two functions, and these findings are not necessarily inconsis-
tent with the unitary hypothesis.
It is also possible that other osmoreceptors reside outside the
14 hypothalamus, perhaps in the oropharynx, liver, or other parts
of the gastrointestinal tract [3, 81. Studies in dehydrated humans
and monkeys suggest that oral water intake can inhibit thirst or
12 AVP release before the fall in plasma osmolality is detectable
[9, 10]. Moreover, clinical as well as animal data showing that
destructive lesions in the hypothalamus abolish the osmoregula-
tion of thirst and/or AVP secretion [II] could be attributed to
interruption of fibres en passage as well as to destruction of
osmoreceptor cells per Se. Even if extracerebral osmoreceptors
exist, they probably are of relatively minor importance because
osmosensitive neurons have been identified only in the hypo-
thalamus [12], and adipsia (as well as deficient AVP secretion)
occurs only in patients with lesions in or around this area.
Absence of thirst does not seem to result from destruction or
denervation of the gastrointestinal tract or any other part of the
body, even if the damage is extensive.
The functional properties of the osmoreceptors that control
2 thirst closely resemble those that regulate AVP secretion (Fig.
2). For practical purposes, both systems can be described in
terms of a threshold receptor, even though it remains unclear
whether thirst and AVP secretion are basically continuous or
episodic processes [13—15]. Thus, at plasma osmolalities below
a certain minimum level, thirst and AVP secretion are consis-
tently low or absent. Above the "threshold" or "set point,"
both functions increase rapidly in direct proportion with plasma
osmolality. The only difference seems to be that the osmotic
threshold for thirst perception is appreciably higher than that
for AVP release (Fig. 2) [16, 17]. Whereas AVP release begins
at an average plasma osmolality of about 280 mOsm/kg, thirst is
not perceived until plasma osmolality exceeds about 290 mOsm/
kg. The latter value approximates the level at which plasma
vasopressin usually reaches a concentration sufficient to pro-
duce a maximum antidiuresis. The thirst mechanism appears to
be set so that it comes into play only when the level of
hypertonic dehydration begins to surpass the protective capaci-
ty of the kidney. This arrangement is ideal, because it permits
maximum use of the antidiuretic mechanism to preserve water
balance, and it frees the individual from the distraction that
otherwise would result from constant thirst.
The thirst mechanism normally provides highly effective
protection against hypertonic dehydration. When the mecha-
nism is fully stimulated, drinking increases so markedly that a
further deficit in body water is largely prevented, no matter how
great the rate of loss. To fully appreciate the capacity of this
mechanism, one only need recall that plasma osmolality tends
to be normal or only slightly increased in adults with familial
nephrogenic diabetes insipidus, even though patients with this
disorder habitually excrete as much as 20 liters of water daily.
The corollary of this observation is that effective renal conser-
vation of water is not essential for successful osmoregulation of
body fluids, provided that the thirst mechanism is operating
properly and that access to water is unrestricted. The only
contribution of antidiuresis to osmoregulation is to lessen
dependence on the thirst mechanism, thereby eliminating the
need to remain constantly close to a water supply. The survival
value of this kind of freedom must have been great for primitive
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Fig. 3. Individual variation in the osmostat in
healthy adults. The top and bottom of each
bar represent, respectively, the osmotic
threshold for thirst and AVP release,
determined by methods exemplified in Figs. I
and 2. The circles within each bar represent
mean basal plasma osmolality in each subject
(open circles, female; closed circles, male).
(Reproduced from Ref. 18.)
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humans, even though it is relatively minor in modern, well-
plumbed civilization.
Paradoxically, vasopressin contributes most to osmoregula-
tion when it ceases to act. By permitting maximal dilution of the
urine, suppression of the hormone increases the rate of water
excretion to a maximum which, if renal function and solute
excretion are normal, can offset all but the most pathologically
excessive rates of water intake. In other words, it is almost
impossible to expand body water to a degree sufficient to dilute
total body solute concentration much below the osmotic thresh-
old for vasopressin release. To fully appreciate the effective-
ness with which ADH suppression acts as a barrier against
hypotonic overhydration, one only has to observe that many
patients with psychogenic polydipsia chronically drink up to 20
liters of water daily without depressing plasma osmolality or
sodium below the normal range. For all practical purposes,
therefore, the osmotic pressure of body fluids is bracketed
within a narrow range, the upper and lower limits of which are
determined by the osmotic thresholds for thirst and AVP
secretion, respectively. Anything that interferes with the full
expression of either function weakens these barriers, thereby
exposing the individual to the hazards of hyper- or
hypotonicity.
The set point" of the osmoreceptors for thirst and AVP
secretion varies appreciably from one healthy person to the
next (Fig. 3) [18]. This variation is sufficiently great that, at the
extremes, the threshold for thirst in one subject can be below
that for AVP release in another. In a given individual, however,
the essential relationship between the two functions is always
preserved. If they were reversed—that is, if the thirst threshold
were below that for AVP release—inappropriate polydipsia and
polyuria would result.
The osmoreceptors for thirst and AVP also show similar
specificities in regard to different plasma solutes. The largest
AVP response is elicited by sodium and its anions (Fig. 4).
Particle for particle, mannitol is almost as potent, whereas urea
and glucose have little or no effect [Ii, 19]. Essentially, the
same rank order of potency is found for thirst. Infusions of
hypertonic saline or mannitol almost always provoke thirst and
do so at comparable levels of plasma hypertonicity (Table I;
Zerbe RL, Robertson GL, unpublished observations). Healthy
adult volunteers were infused with each of the intravenous
solutions for 2 hours. Urea elicited a weak response in a few
subjects, whereas hypertonic glucose did not cause thirst in any
subject. The reason for the different effects of the various
plasma solutes is unknown, but it might be related to the rate at
which these solutes penetrate the osmoreceptor cell. Whatever
the mechanism, these differences must be taken into account
when one interprets thirst and AVP data in patients with
abnormal increases in plasma glucose or urea.
Thirst also can be elicited by a variety of nonosmotic stimuli,
but it is doubtful whether any of these stimuli are important
except under certain pathologic conditions. Patients with
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Fig. 4. Schematic representation of the relationship between plasma
A VP and plasma osmolality in healthy adults during the infusion of
hypertonic solutions of various solutes. (Reproduced from Ref. II.)
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severe hypovolemia, hypotension, or both often complain of
excessive thirst, but thirst rarely if ever occurs in association
with modest reductions in blood volume or blood pressure. For
example, upright posture almost never produces a perceptible
increase in thirst, even though it usually reduces central or
effective blood volume sufficiently to stimulate modest in-
creases in both AVP secretion and plasma renin activity. This
dissociation suggests that, in humans at least, angiotensin II as
well as hemodynamic stimuli are weak or ineffective dipsogens.
Greater activation of the renin-angiotensin system such as that
occurring in renal artery stenosis also fails to produce a notable
increase in thirst. These observations also suggest that, in
regard to the dipsogenic effects of angiotensin, humans differ
substantially from experimental animals such as the rat [20].
A notable exception to the impotence of nonosmotic dipso-
gens in humans is 2-deoxy-D-glucose. This drug, which pro-
duces intracellular glucopenia in brain and somatic cells, causes
a distinct increase in thirst as well as in AVP release [5].
Although the mechanism of this agent's action has not been
determined, it does not seem to be mediated by osmotic or by
any of the other recognized nonosmotic stimuli. The relevance,
if any, of 2-deoxy-D-glucose to clinical disturbances in water
balance also is unknown, but its effects are similar to certain
features of diabetes mellitus; this disease also is characterized
by intracellular glucopenia as well as unexplained increases in
thirst and AVP secretion [21].
Pathophysiology
Hypodipsia. A sustained increase in the effective osmotic
pressure of body fluids almost always is due to inadequate
water intake. This deficit can develop as a result of limited
access to water, such as that occurring in someone marooned in
a desert or paralyzed by a stroke, or it can result from an
intrinsic abnormality in the osmoregulation of thirst.
The latter condition is characterized clinically by chronic or
recurrent hypernatremia associated with an inappropriate lack
of thirst [22—25]. Patients with this condition usually are alert
and active, yet they display no interest in drinking, even when
water is urged on them. The crucial pathogenetic role of their
hypodipsia often has been overlooked, probably because few
clinicians fully appreciate the significance of the patient's
failure to complain of thirst.
Because of misunderstandings about thirst deficiency and the
nature of the AVP deficits that invariably accompany hypodip-
sia, the condition often has been referred to as essential
hypernatremia [22]. This terminology implies that the abnor-
mality in salt and water balance ensues from an upward
resetting of the osmostat. In the few patients in whom these
defects have been thoroughly studied, these alterations proved
to arise from a marked reduction in the sensitivity—the so-
called gain—of the osmostats rather than to an elevation in the
thirst threshold [23—25]. Other studies in these patients have
shown that this hyposensitivity was limited to osmotic stimuli,
since the AVP response to hypotension, nausea, and glucopenia
ranged from normal to supranormal [24, 25]. Hence, both the
adipsia and deficient AVP release appeared to be due to a
selective lesion that destroyed the osmoreceptor while totally
sparing the neurohypophysis and its other regulatory afferents.
This interpretation is consistent with many animal studies in
which experimental lesions in various portions of the anterolat-
eral hypothalamus resulted in abnormalities in osmoregulation
similar to that in the patients [26—30]. These findings do not
exclude the possibility that true resetting of the osmostat occurs
in some patients with chronic hypernatremia. The data do
indicate, however, that considerable care must be exercised in
distinguishing between so-called essential hypernatremia and
simple ablation of osmoregulatory input.
Hypodipsia due to a loss of osmoreceptor function might not
be as rare as previously supposed. Recent studies indicate that
many patients who develop hyperosmolar syndrome have un-
derlying defects in osmotic dipsogenesis [31, 32] as well as
alterations in vasopressin secretion [31]. These patients exhibit
clinical characteristics similar to those in patients with adipsic
hypernatremia and on careful investigation often prove to have
pathology in or around the hypothalamus [31]. When hypergly-
cemia is present in patients with the hyperosmolar syndrome, it
seems to be the consequence rather than the cause of the
dehydration, as rehydration alone usually restores plasma glu-
cose to normal.
Hyperdipsia. Increased thirst can occur as an appropriate
response to hypertonic dehydration or as a result of an abnor-
mal stimulus. Hyperdipsia also can result from some other
motive. For example, patients with psychogenic polydipsia
rarely, if ever, cite thirst as a reason for their habit. Most often
they attribute the hyperdipsia to a motive such as a desire to rid
the body of poison, relieve anxiety, or prevent formation of
renal stones.
Hyperdipsia due to inappropriate thirst has been reported in
association with sarcoidosis involving the central nervous sys-
tem [33]. Our experience has revealed that it also can occur as
an idiopathic defect, sometimes in association with inappropri-
ate antidiuresis (Fig. 5) [34]. In the patients we have studied,
thirst remains responsive to osmotic influences, but the thresh-
old or "set" of the system is abnormally low. Resetting of the
thirst osmostat often is accompanied by a commensurate reduc-
tion in the threshold for AVP release (Fig. 5). As a conse-
quence, patients simply regulate plasma osmolality around a
new, lower set point, and they do not develop polydipsia or
polyuria. Sometimes, however, only the thirst osmostat is
reset, in which case the clinical presentation is that of primary
polydipsia with little or no depression of plasma osmolality or
sodium.
The cause of hyperdipsia in humans has not been determined,
but its assocation with CNS sarcoidosis [33] and lung cancer
(Fig. 5) suggests that destructive lesions of the brain sometimes
Table 1. Effect on thirst of infusing hypertonic solutions of four
different solutes
Solution
Thirst
Number reported Thresho1d (mOsm/kg)
a Threshold values indicate the plasma osmolality (mean SE) at
which a definite increase in thirst was first perceived. The ratios
indicate the number of subjects who reported thirst during the respec-
tive infusions.
might be involved. Such an interpretation would be in accord
with animal studies indicating that destructive lesions in certain
parts of the brain also can increase water intake [35, 36].
Case analysis
How does this background information help us to understand
the cause and treatment of the osmoregulatory dysfunction in
the patient with the hypothalamic tumor whom we are discuss-
ing today7 First, it tells us that her recurrent episodes of
hypernatremia are due to loss of the thirst mechanism. Even
when her plasma osmolality greatly exceeds the normal thresh-
old, she denies thirst and does not drink unless specifically
asked to do so. Since her hypertonicity is solely due to a rise in
plasma sodium and its anions rather than "ineffective" solutes
like glucose or urea, these simple but direct clinical observa-
tions are an unequivocal sign of severe, if not total, loss of
osmotic dipsogenesis. As a consequence, deficits in body water
are not spontaneously replenished and, in the absence of
outside intervention, they inexorably lead to severe dehydra-
tion. This process can and often does occur even in the absence
of excessive water loss, since the minimum obligatory water
output must be replaced. In this patient, however, the minimum
water output might have been accelerated from time to time by
increased water loss secondary to inadequate treatment of her
diabetes insipidus or by her ingestion of extra salt in an effort to
prevent hyponatremia. Neither abnormality would be sufficient
to produce severe hypernatremia if her thirst mechanism were
working properly, however. Hence, hypodipsia is truly the sine
qua non of her condition, and it probably is due to destruction
of hypothalamic osmoreceptors by her tumor, although lesions
in afferent projections to cortical areas that mediate thirst
cannot be excluded.
The patient's lack of thirst also is responsible indirectly for
her intermittent episodes of hyponatremia. Because her need to
replenish body water must be met by an externally imposed
regimen, her intake is difficult to regulate precisely, and it is
sometimes greater than necessary. Normally, the excess water
would be rapidly excreted as a consequence of the osmotically
mediated fall in vasopressin secretion. But because she has
diabetes insipidus as well as hypodipsia, vasopressin must be
given exogenously. Consequently, the important protection
usually afforded by the patient's ability to osmotically suppress
antidiuresis is also lost, and she is unable to excrete a water
load. The resulting hyponatremia is a form of inappropriate
antidiuresis caused by vasopressin therapy. It is a significant
clinical problem in this patient only because of her inability to
regulate water intake. The importance of this factor can be
easily appreciated by remembering that antidiuretic therapy
rarely, if ever, leads to significant hyponatremia in patients with
uncomplicated diabetes insipidus, because their thirst mecha-
nism is intact [37].
The potentially lethal combination of hypodipsia and diabetes
insipidus poses an exceptionally difficult therapeutic challenge.
Trying to prevent the extremes of hyper- and hyponatremia is
like trying to walk a tightrope without a safety net. In my
experience, the best approach is a combination of standard
antidiuretic therapy with a closely monitored regimen of water
intake adjusted daily in accordance with physiologic need. The
latter can be monitored in the hospital by daily measurements of
plasma sodium, osmolality, and body weight. In an ambulatory
Plasma osmolality
(mOsm/kg)
Fig. 5. Relationship of plasma A VP and thirst toplasma osmolality in a
patient with lung cancer and inappropriate antidiuresis. Note that both
functions respond normally to changes in osmolality except the thresh-
olds for thirst (vertical arrow) and AVP release (X-intercept of regres-
sion line) are subnormal. (Reprinted by permission of the publisher
from Cancer and inappropriate antidiuresis, by GL Robertson, in
Biological Markers of Neoplasia: Basic andAppliedAspects, edited by
RW Ruddon, pp 277—293. Copyright 1978 by Elsevier Science Publish-
ingCo., Inc.).
setting, changes in body weight provide the only practical
guide. The patient should be provided with a schedule that
prescribes water intake as a function of deviations from an ideal
or target weight (Table 2). In constructing such a scale, one
must determine the average minimum daily loss for the patient,
and take into account the water content of a standard diet. It is
also wise to establish limits that signal levels of water imbalance
that require calling the physician. In a child, one must recali-
brate the target weight periodically to adjust for growth. In all
cases, plasma sodium should be checked every 3 to 6 months to
verify hydration status.
Adjustments in salt intake play no role in the treatment of
these patients; the changes in their plasma sodium concentra-
tion all are secondary to changes in total-body water. If
anything, salt intake should be kept relatively constant to
minimize changes in solute load and consequent changes in
urine output. Treatment with chlorpropamide has been advo-
cated as a means of promoting both antidiuresis and thirst [38—
411. In my experience, chiorpropamide offers few advantages
over the regimen described and certainly does not eliminate the
need for a regular schedule of water intake. In any event, the
management of these patients is a demanding task that leaves
the physician with a profound respect for the effective and
unobtrusive way in which water balance is constantly regulated
by normal homeostatic mechanisms.
Questions and answers
DR. DAVID BUSHINSKY (Renal Section, Billings Hospital,
Chicago): We know that the gastrointestinal tract has receptors
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Table 2. Typical schedule for management of a patient with adipsic
hypernatremia
Target weight: 70 kg
Average minimum daily output
Source:
Standard daily prescribed intake
Source:
Below target
1kg
2 kg
3 kg
4 kg
5 kg or more:
Above target
+l000ml
+2000 ml
+3000 ml
+4000 ml
Contact physician
3000m1
4000 ml
5000 ml
6000 ml
1 kg
2 kg
3 kg or more:
—1000 ml
—2000 ml
Contact physician
1000 ml
Dry food only
for certain hormones such as the mineralocorticoids. Does the
gastrointestinal tract have receptors for AVP, and does it
contribute to the regulation of water balance in any significant
way?
DR. ROBERTSON: The explosive cramps and diarrhea pro-
duced in humans by large doses of vasopressin provide dramat-
ic, albeit circumstantial, evidence that the gastrointestinal tract
probably does contain receptors for the hormone. However,
that's a smooth muscle effect, and you are talking about water
permeability, which probably involves different receptors.
There is some evidence that vasopressin might affect water
absorption in the colon and other enteric organs, but that
question has not been worked out very well as yet.
DR. JORDAN J. COHEN: Have efforts been made to use the
new technique of positron-emission tomography (PET) to local-
ize and monitor the cerebral response to thirst? Will this be a
useful approach?
DR. ROBERTSON: To my knowledge, it has not been tried, but
we are very interested in undertaking that very study. Using the
PET scans or some of the other methods of detecting thirst-
specific changes in metabolic activity in the cerebral cortex
obviously would be valuable to clinical dipsologists because it
would provide a good way of objectively assessing thirst.
Moreover, it also would be of interest to know whether
localized cortical projections of thirst exist as for other senses
such as sight and sound.
DR. ROBERT A. STAR (Medical Resident, Michael Reese
Hospital): We know that ADH receptors are present in the
thick ascending limb [42—44]. Do you have any thoughts about
what function they might serve?
DR. ROBERTSON: I really don't know, but I can speculate.
There are reports that, at least in certain species, ADH pro-
motes sodium excretion by exerting a direct effect on renal
tubules. Whether the receptors you are talking about in the
ascending limb play a role in that effect, I don't know. I do
know that in humans it is very difficult to demonstrate any
effect of vasopressin on sodium excretion independent of
changes in water balance. In other words, administering a large
amount of ADH to somebody does not produce any changes in
sodium excretion if you prevent positive water balance, In
certain animals one can demonstrate an independent natriuretic
2000 ml effect. Hence, it is possible that in certain species, stimulating
sodium excretion is another way of controlling hypertonic
dehydration. In humans, however, it does not seem to be a very
important mechanism.
DR. BRIAN DUFFY (Attending Nephrolo gist, Michael Reese
Hospital): Hypokalemia has been shown to stimulate primary
polydipsia in animals before it causes any detectable renal
effects [45]. How do you fit this observation into your scheme?
DR. ROBERTSON: Again, I can only speculate. If the set of the
osmoreceptor depends in part on intracellular solute content—
as it might, for example, if it corresponded to the null point at
which there is no net water flux in or out of cells—then a
depletion of total-body potassium or other intracellular solute
would in effect lower the set of the osmoreceptor by decreasing
the level of plasma osmolality at which such equilibrium occurs.
The problem with that theory is that the osmoregulation of
vasopressin secretion in hypokalemic animals is not associated
with significant resetting. Instead, it is characterized by a
marked reduction in the sensitivity of the response to osmotic
stimuli. And that is contrary to the change one would expect to
find if intracellular solute were crucial in determining either
functional property of the osmoreceptor. Thus, I cannot answer
your question at present.
DR. COHEN: The mild hypernatremia characteristic of pa-
tients with primary aldosteronism has several possible explana-
tions. It might reflect: (1) a reduced sensitivity to thirst caused
by the attendant volume expansion; (2) the renal concentration
defect and the polyuria attributable to hypokalemia; or (3) a
direct effect of hypokalemia on the thirst mechanism. Do you
know of any data that would allow us to distinguish among
these possibilities?
DR. ROBERTSON: Yes. In the patients we studied, it was not
possible to separate out the effect of changes in serum potassi-
um from the changes in extracellular volume since both abnor-
malities were corrected simultaneously. Other evidence argues
against an important role for hypokalemia or polyuria in the
hypernatremia, however. In experimental animals made hypo-
kalemic by administration of a potassium-absorbing resin, one
does not find hypernatremia or the same changes in the set of
the osmostat that occur in patients with primary hyperaldoste-
ronism. Moreover, as noted earlier, hypokalemia can cause
primary polydipsia, and this change ought to reduce the plasma
sodium level. Finally, the mild polyuria present in some of these
patients is insufficient to account for the hypernatremia. Poly-
uria of equal or greater degree occurs in patients with diabetes
insipidus but does not result in the same degree of
hypernatremia.
DR. COHEN: Hypervolemia is also a feature of patients with
SIADH. In keeping with your thesis, increased volume might
be expected to suppress thirst. Yet patients with SIADH often
become profoundly hyponatremic, obviously because they con-
tinue to imbibe water. How do you rationalize the occurrence
and persistence of profound hyponatremia in such patients who
should have both a nonosmotic, volume-mediated and an
osmotic inhibition of thirst?
2000 ml
Renal 1000 ml
Extrarenal 1000 ml
Food 1000 ml
Drink 1000 ml
Daily adjustments for changes in weight
Weight
(kg)
Adjustment
(ml)
Total intake
(including food)
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DR. ROBERTSON: One reason, as I said before, is that volume
is a relatively unimportant factor in thirst, at least in humans.
You must produce an enormous decrease in blood volume,
much larger even than that required to stimulate vasopressin
secretion, before thirst is stimulated. The inhibitory effect of
hypervolemia is less easy to document but is probably also
minor. Hence, I don't have any problem understanding why
patients with SIADH remain thirsty in the presence of the mild
volume expansion characteristic of that syndrome. I do have a
little difficulty understanding why they continue to drink when
hyponatremic, however. Many of them probably have an
inappropriate stimulus to thirst as well as to vasopressin. Some
of them appear to have resetting of both the thirst osmostat and
the ADH osmostat. In other words, both thirst and vasopressin
secretion are "turned on" at a much lower than normal level of
plasma osmolality. As a consequence, patients with inappropri-
ate secretion of antidiuretic hormone simply osmoregulate
around a new, lower level. But that mechanism is operative in a
minority of cases. Many other patients with SIADH do not
appear to have an abnormality in thirst. We can presume that
their water intake is excessive for another reason. For example,
we recently treated a patient with chronic SIADH who got a
cold and was told by his physician to increase his fluid intake.
He did and was hospitalized several days later with convulsions
and a plasma sodium of 112 mEq/liter. Another typical example
is a patient who is admitted to the hospital with a stroke,
pneumonia, or lung tumor, and who has a normal serum sodium
level. Well-meaning physicians administer 2 to 3 liters of fluid
per day, and next thing you know, the patient is hyponatremic.
In all likelihood, the patient did not develop SIADH while in the
hospital, but had it on admission and simply did not drink
enough to bring out the defect. In the process of administering
intravenous fluids, we simply bring out a preexisting problem.
DR. COHEN: Is there any evidence that ADH itself is a
dipsogen?
DR. ROBERTSON: In dogs ADH has been reported to be
dipsogenic, but I am skeptical that plasma vasopressin has that
effect in humans. The administration of standard diagnostic
doses of Pitressin to patients produces elevations in plasma
vasopressin 10 to 20 times the normal level, yet none of these
individuals ever report thirst. Vasopressin also is present in
cerebrospinal fluid. It does not get there from plasma, but is
secreted directly into cerebrospinal fluid, apparently in re-
sponse to osmolality and many of the other stimuli that regulate
its release into blood. Why vasopressin is in cerebrospinal fluid,
we don't know. It is present in normal or increased amounts in
the CSF of patients with diabetes insipidus, even though they
have no measurable vasopressin in their plasma [461. So, it is
conceivable that the vasopressin secreted in the cerebrospinal
fluid is playing some role in dipsogenesis.
DR. JULIA GLYNN (Medical Resident, Michael Reese Hospi-
tal): Patients with diabetes insipidus who have an intact thirst
response get along reasonably well, as you noted. What hap-
pens to patients with the opposite combination, that is, a normal
ADH mechanism but an abnormal thirst mechanism? Are there
such patients?
DR. ROBERTSON: We have not identified any patients with
normal vasopressin levels and hypodipsia. If such patients
exist, I would expect them to exhibit chronic or recurrent
hypernatremia. We have studied one patient with polydipsia in
the presence of completely normal vasopressin secretion and
action. She became thirsty at a much lower level of plasma
osmolality than do normal persons. In fact, her thirst threshold
was below the set of her ADH osmostat. She has no organic
disease that we can associate with this abnormality. Through-
out a 3-year period, she has continued to excrete 6 to 8 liters of
urine daily. When given DDAVP, she retained water and
became hyponatremic, and her thirst ceased. We have not
continued the treatment, however, because we decided that it
was better not to expose her to chronic hyponatremia.
DR. COHEN: Is a resetting of the thirst threshold a possible
explanation for so-called psychogenic polydipsia?
DR. ROBERTSON: I don't think so. Psychogenic polydipsia is a
subset of primary polydipsia that occurs in schizophrenia and
other psychoses. As I mentioned earlier, these patients rarely
ever give thirst as the reason for their water intake. If you ask
them, they give irrational reasons such as "They are trying to
poison me and I'm washing them out of my system." These
patients rarely use the word thirst. And if these patients are
treated with any form of antidiuretic, severe, even fatal hypona-
tremia can occur because they don't shut off their water intake.
In many other patients with the nonpsychogenic forms of
primary polydipsia, we might in fact be dealing with a primary
abnormality in the thirst mechanism that in some cases might be
due to abnormal resetting of the thirst osmostat with or without
associated abnormalities in the osmoregulation of vasopressin.
DR. BUSHINSKY: Patients with chronic hypernatremia are
thought to form idiogenic osmoles in the CNS that prevent
excessive brain shrinkage due to osmolar gradients. When
repleting such patients with water, we want to restore normal
osmolality as quickly as possible to avoid more hyperosmotic
CNS injury, yet we don't want to go too fast and cause brain
swelling. What are your thoughts about the rapidity with which
a hypernatremic patient should be repleted with water?
DR. ROBERTSON: In patients who have hyperosmolar syn-
drome in association with hyperglycemia, one needs to proceed
slowly—that is, to lower the plasma osmolality over a period of
24 to 48 hours. Otherwise, the increase in intracellular solute,
which prevents severe brain dehydration during hyperosmolali-
ty, will cause rapid and excessive water uptake and brain edema
as extracellular osmolality falls towards normal. In patients in
whom the hyperosmolarity is due to pure hypernatremia with
no hyperglycemia, I don't know whether rapid rehydration is
hazardous. There is no great urgency to rehydrate because
patients, as a rule, will have been hyperosmolar for a long time
and are unlikely to be adversely affected by another 24 to 36
hours of hyperosmolarity.
DR. ADRIAN KATZ (Renal Section, Billings Hospital, Chica-
go): What about the opposite side of the question, namely, the
speed of correction of hyponatremia? There are case reports of
central pontine myelinolysis following rapid correction of hy-
ponatremia with hypertonic saline. What are your thoughts
about these cases? How rapidly should we correct hyponatre-
mia? Are there levels at which we should repair the abnormality
faster or slower?
DR. ROBERTSON: We use hypertonic saline infusions routine-
ly in patients with severe, symptomatic hyponatremia, that is,
in those who have plasma sodium levels in the range that causes
stupor or convulsions. We can't afford to treat these patients
with water restriction alone because, as you know, such an
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approach can take days to correct hyponatremia. We have used
hypertonic saline infusion in approximately 70 or 80 of these
patients over the years and have never seen any adverse
neurologic or other effects in them. We infuse 5% saline at a
rate of 0.05 mI/kg/mm. Over the course of 2 hours, this
treatment usually causes plasma osmolality to increase by
about 12 to 15 mOsm/kg, and plasma sodium to rise by about 7
mEq/liter. This degree of improvement may not completely
correct the defect, but it is usually sufficient to bring the patient
out of danger. I think that continued hyponatremia, particularly
if associated with obtundation or convulsions, poses a much
greater hazard to patients than does hypernatremia and, conse-
quently, deserves more urgent treatment.
DR. COHEN: You noted that administration of hypertonic
glucose has a strikingly different effect on thirst and ADH
release than does hypertonic saline or mannitol; you hypothe-
sized that this difference, due to the rapid penetration of glucose
into cells, minimized the effect on the volume of the osmorecep-
tor cell. We commonly think about glucose as being a potent,
osmotically active agent, capable of drawing water out of body
cells and producing hyponatremia. Is there something different
about the behavior of neurons in this regard?
DR. ROBERTSON: It would appear that glucose uptake in most
neurons is independent of insulin. By contrast, the entry of
glucose into most somatic cells is dependent on insulin and, as a
result, is a rate-limited phenomenon. Therefore, in the diabetic
who lacks insulin or even in the normal individual, a sufficiently
rapid increase in plasma glucose can saturate the capacity of
somatic cells to take up this substance, The existence of
osmotic disequilibrium across somatic cell membranes in these
situations is evidenced by a fall in plasma sodium that results
from the intra- to extracellular shift of water. In neuronal tissue,
glucose uptake is not a saturable process, and the kind of
osmotic gradient required to produce cellular dehydration does
not occur, provided the rate of glucose metabolism is slow
relative to the rate of entry.
DR. CaIG LANOMAN (Pediatric Nephrology Division, Mi-
chael Reese Hospital): In view of the availability of closed-loop
insulin pumps that respond to changes in glucose, do you see a
future role for an infusion pump capable of administering ADH
in response to changes in plasma osmolality?
DR. ROBERTSON: Such a pump would certainly have been of
great help in the patient that we talked about today. However, I
am not sure whether there are enough such patients to make
development of such a device commercially worthwhile. It
probably would not confer any advantages in the treatment of
the typical patient with diabetes insipidus, because the thirst
mechanism usually operates well enough to avoid the extremes
of overhydration that might otherwise result from a fixed,
osmotically unresponsive rate of vasopressin delivery.
Reprint requests to Dr. G. Robertson, Director of Clinical Research
Center, University of Chicago Hospital, Box 131, 950 East 59th Street,
Chicago, Illinois 60637
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